Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date10 Oct 2010 |
A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers
The hypothesis was to establish whether the use of PrevinC administered nasally 2-3 times a day will prevent upper respiratory infections in otherwise healthy adults working in child day care centers.
100 Clinical Results associated with BioHealth Technologies Inc.
0 Patents (Medical) associated with BioHealth Technologies Inc.
100 Deals associated with BioHealth Technologies Inc.
100 Translational Medicine associated with BioHealth Technologies Inc.